Abstract
Paclitaxel (Taxol), one of the most important anticancer drugs, has been used for therapy of different types of cancers. Mechanistically, paclitaxel arrests cell cycle and induces cell death by stabilizing microtubules and interfering with microtubule disassembly in cell division. Recently, it has been found that low-dose paclitaxel seems promising in treating non-cancer diseases, such as skin disorders, renal and hepatic fibrosis, inflammation, axon regeneration, limb salvage, and coronary artery restenosis. Future studies need to understand the mechanisms underlying these effects in order to design therapies with specificity.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 279-284 |
| Number of pages | 6 |
| Journal | Drug Design, Development and Therapy |
| Volume | 8 |
| DOIs | |
| State | Published - Feb 20 2014 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Coronary artery restenosis
- Fibrosis
- Kidney
- Limb salvage
- Taxol inflammation
ASJC Scopus subject areas
- Pharmacology
- Pharmaceutical Science
- Drug Discovery
Fingerprint
Dive into the research topics of 'Paclitaxel: New uses for an old drug'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS